Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer

Surgery Clinical Trial

— TLTME  

Official title:

Transanal Versus Laparoscopic Total Mesorectal Excision for Mid And Low Rectal Cancer in China (TLTME): a Single-center Randomized Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03359616
• Other study ID #: MISC-TaTME
• Status: Not yet recruiting
• Phase: N/A
• First received: November 26, 2017
• Last updated: November 30, 2017
• Start date: January 1, 2018
• Est. completion date: January 1, 2022

Study information

• Verified date: November 2017
• Source: Shanghai Minimally Invasive Surgery Center
• Contact: Minhua Zheng, M.D., PhD.
• Phone: 0086-13564119545
• Email: zmhtiger[@]yeah.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Total mesorectal excision (TME) has been prevailingly accepted as a crucial surgical intervention within the latest oncological therapeutic regime for mid-low rectal cancer. However, surgical dissection under the restricted pelvic anatomical structure, added by obesity and many other general factors, remains challenging for classical open and laparoscopic patterns, particularly in male cases. The introduction of transanal total mesorectal excision (TaTME) offers an optimal pattern for the surgical resection of mid-low rectal cancer, circumventing the conventional anatomical limits while bringing forward considerable advantages by direct dissection. Noteworthy, the surgical techniques of TaTME is initially established, with the mortality/morbidity and the oncological safety unverified. The studies that focus on the comparison between TaTME and laparoscopic TME (LaTME) remain sparse. Therefore, the features of TaTME, both in short and long terms, await further consolidation by clinical trials. Herein, this single centered, interventional study protocol is established to collect initial clinical data on both the safety and efficacy of the TaTME in comparison with LaTME in East Chinese patients with mid-low rectal cancer.

Description:

Background: Transanal total mesorectal excision (TaTME) is increasingly accepted as one of the alternative patterns for the resectable rectal cancer worldwide since its first appearance. For mid-low rectal cancer, TaTME features superior viewpoints and direct access to mobilize the primary lesion without the pelvic anatomic limits. Therefore, the matured TaTME technique could deliver satisfactory clinic outcomes in both surgical and oncological senses. However, the studies that designed to compare the feasibility and repeatability of TaTME with conventional laparoscopic total mesorectal excision (LaTME) remain sparse and limited.

Study Objective: Evaluation of short-term mortality and morbidity, long term overall survival and disease-free survival as well as quality of life in rectal cancer patients in East China.

Study Design: This study is a prospective, single-center, randomized clinical trial with a central monitored electronic data processing system. Corresponding randomization, data collection and comparative analysis will be conducted based on the research group discussion. According to the non-inferiority principle, the power is 80% and the α is 0.05 with 10% margin delta (δ). Total patients will be 258, with 129 in each group given 10% lost in follow-up.

Study Endpoints: The primary outcomes measures will be the Disease-free survival (3-years). The secondary outcomes measures will be overall survival (3-years), mesorectal completeness (the quality of the TME specimen, complete, near complete, incomplete), positive circumferential resection margin (CRM), number of retrieved lymph nodes, morbidity rate, mortality rate.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 258
• Est. completion date: January 1, 2022
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Rectal adenocarcinoma validated by pathologists, pathological estimated stage II-III;

2. Mid and low rectal tumor sites, parameter less than 5cm, below the level of peritoneal reflection and verified by MRI, distance to anus less than 7 cm;

3. Curative rectal cancer surgery;

4. No evidence of distance metastasis lesions;

5. T1-3, N0-2, with or without neoadjuvant therapeutic history;

6. Applied to laparoscopic surgery;

7. Absent of previous malignancy-treated history

8. No gender restriction, age between 18 and 75, Body Mass Index less than 32;

9. Approved by multiple disciplinary teamwork therapeutic group

10. Consent by the patient and the family.

Exclusion Criteria:

1. Mile's surgery is additionally required;

2. Tumor invasion is validated on adjacent organs, such as prostate;

3. Recurrent rectal cancer, require secondary surgical interventions;

4. Previous history of malignant diseases or inflammatory bowel diseases within recent five years;

5. Emergent surgery accompanied by bowel obstruction or intestinal perforation;

6. Previous history of colorectal surgery, unnatural anatomical structure;

7. Contraindication to general anesthesia (class IV or V in American Society of Anesthesiologists (ASA), or Eastern Cooperative Oncology Group (ECOG) score >=2)

8. Pregnant or breast-feeding patients;

9. Mental disorder validated by psychiatrists.

10. Uncontrolled infectious diseases;

11. Participants within other related clinical trials that may influence the conclusion of this trial;

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms
• Surgery

Intervention

Procedure:
• Transanally curable surgical resection
Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
• Laparoscopic total mesorectal excision
Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Minimally Invasive Surgery Center

References & Publications (4)

Bulut O, Levic K, Hesselfeldt P, Bülow S. The outcome of rectal cancer after early salvage TME following TEM compared with primary TME: a case-matched study. Tech Coloproctol. 2014 Jan;18(1):83-4. doi: 10.1007/s10151-013-1083-y. Epub 2013 Nov 6. — View Citation

Fernández-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Díaz del Gobbo G, DeLacy B, Balust J, Lacy AM. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg. 2015 Feb;261(2):221 — View Citation

Martin-Perez B, Andrade-Ribeiro GD, Hunter L, Atallah S. A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013. Tech Coloproctol. 2014 Sep;18(9):775-88. doi: 10.1007/s10151-014-1148-6. Epub 2014 May 7. Review. — View Citation

Motson RW, Whiteford MH, Hompes R, Albert M, Miles WF; Expert Group. Current status of trans-anal total mesorectal excision (TaTME) following the Second International Consensus Conference. Colorectal Dis. 2016 Jan;18(1):13-8. doi: 10.1111/codi.13131. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival (DFS)	3-year DFS	3-years
Secondary	Overall survival (OS)	3-years OS	3-years
Secondary	mesorectal completeness	(the quality of the TME specimen, complete, near complete, incomplete)	3-years
Secondary	positive circumferential resection margin	the rate of positive circumferential resection margin (CRM)	3-years
Secondary	number of retrieved lymph nodes	retrieved lymph nodes	3-years
Secondary	morbidity rate	morbidity rate(number of intr-and post-operative encountered cases)	3-years
Secondary	mortality rate	(number of intr-and post-operative encountered complications)	3-years